Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Breast Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
48 drugs · 217 active trials
17 drugs · 330 active trials
43 drugs · 1,254 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 13 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Alvespimycin | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2004-07 |
| Alvocidib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 1998-12 |
| Bendamustine | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2005-07 |
| Cixutumumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Jul 30, 2008 |
| Dordaviprone | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2014-01 |
| Dovitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Jan 27, 2012 |
| Enzastaurin | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2007-03 |
| Estramustine | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 1997-02 |
| Futibatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Jul 21, 2014 |
| Lucitanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2013-12 |
| Luminespib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2007-07 |
| Mirvetuximab Soravtansine | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Mar 22, 2017 |
| Nintedanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2013-05 |
| Pilaralisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2008-06 |
| Ridaforolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2008-07 |
| Seribantumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2011-10 |
| Tanespimycin | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 1999-07 |
| Vemurafenib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Apr 1, 2020 |
| Aflibercept | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2007-01 |
| Alectinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Oct 7, 2020 |
| Alemtuzumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2005-01 |
| Amrubicin | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2009-12 |
| Apitolisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2010-12 |
| Capmatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jan 31, 2019 |
| Chloroquine | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2009-12 |
| Dual IGF-1R/InsR Inhibitor BMS-754807 | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2009-07 |
| Foretinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Sep 2, 2010 |
| Fruquintinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Dec 11, 2017 |
| Ganitumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Mar 27, 2008 |
| Lurbinectedin | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jun 13, 2012 |
| Motesanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2006-12 |
| Nirogacestat | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Feb 3, 2015 |
| Pemigatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Feb 27, 2015 |
| Perifosine | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2003-06 |
| Ponatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Apr 1, 2020 |
| Prednisolone | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2008-05 |
| Prexasertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jun 18, 2014 |
| Retaspimycin Hydrochloride | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2008-04 |
| Sulindac | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2002-01 |
| Teprotumumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jan 28, 2009 |
| Thalidomide | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2001-04 |
| Topotecan | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2000-03 |
| Valproic Acid | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Oct 16, 2012 |
| Vatalanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2005-01 |
| 7-Ethyl-10-Hydroxycamptothecin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2009-02 |
| Anti-PD1 Monoclonal Antibody | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Dec 1, 2022 |
| Arsenic Trioxide | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2002-11 |
| AZD-4547 | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-09 |
| Bazedoxifene | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 9, 2015 |
| Bimiralisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 28, 2016 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.